PLRX
Pliant Therapeutics, Inc.
There isn't enough reported data to score PLRX yet.
PLRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Strong |
PLRX's balance sheet is currently strong, but its revenue and profitability are weak. There isn't enough data to rate its cash flow.
PLRX PE Valuation
PLRX has no meaningful PE right now: it lost money over the past year.
PLRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect PLRX's revenue to grow, with its earnings and profitability holding steady.
PLRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | +$1.44 |
| Q2 2026 | -$1.48 | +$1.92 |
| Q1 2026 | -$1.83 | +$1.78 |
| Q4 2025 | -$2.43 | +$1.04 |
| Q3 2025 | -$2.88 | +$0.45 |
| Q2 2025 | -$3.40 | -$0.32 |
| Q1 2025 | -$3.61 | -$0.75 |
| Q4 2024 | -$3.47 | -$0.72 |
PLRX is still losing money, but far less than before: $1.44 per share over the past year, against $3.61 at its worst in early 2025.
PLRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $248K | -95% |
| Q1 2023 | $1.3M | +6.6% |
| Q4 2022 | $2M | -1.7% |
| Q3 2022 | $1.5M | -8% |
| Q2 2022 | $5M | +179% |
| Q1 2022 | $1.2M | -43% |
| Q4 2021 | $2M | -55% |
| Q3 2021 | $1.6M | -67% |
PLRX's revenue has slid since its 2019 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -19084% | -18490 points |
| Q1 2023 | -3160% | -902 points |
| Q4 2022 | -1903% | -673 points |
| Q3 2022 | -2156% | -472 points |
| Q2 2022 | -594% | +686 points |
| Q1 2022 | -2259% | -1205 points |
| Q4 2021 | -1231% | -805 points |
| Q3 2021 | -1684% | -1338 points |
PLRX's operating margin was −19084% last quarter, down 18490 points from the same quarter a year ago, near the bottom of its range since 2019.
PLRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17M | +$4.1M |
| Q2 2026 | -$12.8M | +$27.9M |
| Q1 2026 | -$19.2M | +$29.9M |
| Q4 2025 | -$17.8M | +$30.1M |
| Q3 2025 | -$21.1M | +$12.1M |
| Q2 2025 | -$40.7M | +$5.8M |
| Q1 2025 | -$49.1M | -$17.4M |
| Q4 2024 | -$47.9M | -$22.7M |
PLRX has burned cash in almost every quarter: −$67M over the past year, against −$159M the year before.
PLRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +24.7K shares |
| 1 year | +0.9% | +537K shares |
| 3 years | +3.8% | +2.3M shares |
| 5 years | +73% | +26.2M shares |
| Available history | +184% | +40.1M shares |
PLRX has 62M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
PLRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2020 | -2.7x | Net Cash |
| Q2 2020 | -7.4x | Net Cash |
| Q1 2020 | -4.5x | Net Cash |
PLRX has more cash than debt.
PLRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 4.0 | Oversold |
PLRX's weekly RSI is 26 (oversold) and its Stochastic is 4 (oversold).
PLRX PE vs Healthcare Sector
| Metric | PLRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PLRX has no meaningful PE right now: it lost money over the past year.
PLRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.91 | 19% below |
| 20 week MA | $1.04 | 29% below |
| 50 week MA | $1.15 | 36% below |
| 100 week MA | $2.19 | 66% below |
| 200 week MA | $9.83 | 92% below |
PLRX is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
PLRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.3 | $25.4 | +14% |
| 2021 | $25.4 | $15.4 | -40% |
| 2022 | $15.4 | $18.2 | +19% |
| 2023 | $18.2 | $18.1 | -0.5% |
| 2024 | $18.1 | $13.6 | -25% |
| 2025 | $13.6 | $1.21 | -91% |
| 2026 YTD | $1.21 | $0.74 | -39% |
PLRX has finished three years in a row lower, and it's down 39% so far in 2026.